Litcius/Paper detail

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O’Dwyer, Martha Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick J. Stiff, Deepa Jeyakumar, Chaoling Feng, Jinghui Dong, Tong Shen, Francesca Milletti, John M. Rossi, Remus Vezan, Behzad Kharabi Masouleh, Roch Houot

2021The Lancet770 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineMinimal residual diseaseRefractory (planetary science)LeukapheresisGastroenterologyPhases of clinical researchPopulationSurgeryChemotherapyBone marrowStem cellCD34BiologyGeneticsEnvironmental healthAstrobiologyPhysicsCAR-T cell therapy researchAcute Lymphoblastic Leukemia researchLymphoma Diagnosis and Treatment
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study | Litcius